Bruno Pougault: Oral Anticoagulants Are Essential, But Not a ‘Fix-All’
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn about a recent article by Eva Soler-Espejo et al, published in JAHA:
”Oral anticoagulants: Essential, but not a ‘fix-all’.
A huge thank you to the authors of this recent study in JAHA (DOI: 10.1161/JAHA.125.046694) for highlighting the reality of residual risk.
Even with optimal treatment, the risk of stroke in AFib patients persists.
This research is a vital reminder that we must look beyond the prescription: managing comorbidities and lifestyle remains just as crucial as the medication itself.
Great work by the team for pushing the boundaries of comprehensive cardiovascular care!”
Title: Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort
Authors: Eva Soler-Espejo, Yang Chen, José M. Rivera-Caravaca, María P. Ramos-Bratos, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip
Read the Full Article on JAHA
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition